News >

Expanding the Treatment Toolbox in ESR1-Mutant Breast Cancer

Kristi Rosa
Published: Friday, Dec 06, 2019

Daniel Stover, MD, an assistant professor of medicine, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center

Daniel Stover, MD

Although patients with estrogen receptor (ER)–positive, HER2-negative breast cancer who harbor ESR1 mutations currently have a poor prognosis, novel approaches are emerging in an effort to improve outcomes for this population, said Daniel Stover, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x